secwatch.observer — SEC 8-K summary
======================================

Issuer:     Schrodinger, Inc. (SDGR)
CIK:        0001490978
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001490978-23-000047
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Schrödinger Q1 revenue $64.8M (+33%), net income $129.1M on $147M Nimbus gain
-----------------------------------------------------------------------------

- Drug discovery revenue $32.6M (up 109% YoY) includes $25M BMS milestone for SOS1/KRAS program.
- Software revenue $32.2M (down 3% YoY); gross margin 78%.
- Cash from Nimbus TYK2 sale $147.3M; total cash and securities $532M at quarter-end.
- Phase 1 dosing ongoing for SGR-1505 (MALT1) in B-cell malignancies and healthy volunteers.
- Guidance reaffirmed: software revenue growth 13-17%, drug discovery $70-90M; operating expense growth to moderate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1490978/000149097823000047/0001490978-23-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1490978/000149097823000047/sdgr-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001490978-23-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer